Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan
Recruitment Has Commenced for the First-Of-Its-Kind, U.K. - based Study, Led by Renowned Ketamine Researcher
- The study will be led by Celia Morgan, Ph.D., Professor of Psychopharmacology at the University of Exeter, U.K., Awakn's Head of Ketamine-Assisted Psychotherapy for Addiction and an internationally respected expert in the therapeutic use of ketamine.
- The study will investigate a new treatment approach for gambling addiction, tackling both the urge to gamble and the "superstitious thinking" that accompanies gambling.
- The study will explore whether ketamine administration can modify the reward memories associated with gambling.
- About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic medicine to better treat addiction.